Navigation Links
Media Advisory - Oncolytics Biotech Inc. to Present at Maxim Group Growth Conference
Date:10/2/2008

CALGARY, Oct. 2 /PRNewswire-FirstCall/ - Dr. Brad Thompson, President and CEO of Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY), will present a corporate overview of the Company at the Maxim Group Growth Conference at 2:30 p.m. ET on Tuesday, October 7, 2008. The event is being held at the Grand Hyatt Hotel in New York.

A live audio link to the webcast presentation is available at http://www.wsw.com/webcast/maxim/oncy/ on the company's website at http://www.oncolyticsbiotech.com. It is recommended that listeners log on 15 minutes in advance of the presentation to register and download any necessary software.

An audio replay will be accessible on the Oncolytics website following the presentation.

About Oncolytics Biotech Inc.

Oncolytics is a Calgary-based biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics. Oncolytics' clinical program includes a variety of Phase I/II and Phase II human trials using REOLYSIN(R), its proprietary formulation of the human reovirus, alone and in combination with radiation or chemotherapy. For further information about Oncolytics, please visit http://www.oncolyticsbiotech.com

About the Maxim Group Growth Conference

The Maxim Group Growth Conference will feature interactive presentations from over 80 companies, as well as one-on-one meetings with executives from the healthcare, technology, shipping/transportation and emerging growth sectors. Attendees will include securities analysts, fund managers and institutional investors.

The presentation time is subject to change. This release and the presentation related thereto contain forward-looking statements which involve known and unknown risks, delays, uncertainties and other factors not under the Company's control and which may cause actual results, performance or achievements of the Company to be materially different from the results, performance or expectations implied by these forward-looking statements. Such risks and uncertainties include, among others, the efficacy of REOLYSIN(R) as a cancer treatment, the success and timely completion of clinical studies and trials, uncertainties related to the research and development of pharmaceuticals and uncertainties related to the regulatory process. Investors should consult the Company's quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statements. Investors are cautioned against placing undue reliance on forward-looking statements. The Company does not undertake to update these forward-looking statements, except as required by applicable laws.


'/>"/>
SOURCE Oncolytics Biotech Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Cell Therapeutics Provides Details on Investor & Media Day to be Held in Milan, Italy on Friday, October 3, 2008
2. Huifeng Bio-pharmaceutical Technology Inc. Announces Strategic Alliance with Premier Media Service Inc.
3. U.S. News Media Group Releases 19th Edition of Americas Best Hospitals
4. VIDEO from Medialink and Med-El: New Technology is Music to Peoples Ears
5. BioLife Solutions Announces FDA Master File Acceptance for CryoStor(TM) Pre-formulated Cryopreservation Media
6. Bayer HealthCare Pharmaceuticals Introduces VistaTrak(TM) an Innovative Contrast Media Management System
7. Media Advisory - Oncolytics Biotech Inc. to Present at BioSquare 2008
8. Media Advisory - Oncolytics Biotech Inc. to Present at Bio CEO & Investor Conference
9. Intellisphere Announces Acquisition of Multiple Titles from Ascend Medias Healthcare Division
10. In response to a New England Journal of Medicine article published yesterday and subsequent media coverage, Eli Lilly and Company issued the following statement:
11. Study Examines Media Preferences of Life Scientists in Applied Markets
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/15/2017)... ... 15, 2017 , ... Coffea arabica accounts for 70 percent ... During this educational webinar, participants will learn about the importance of genomics for ... understanding of how genomics is important for coffee breeding improvement. , Attendees will ...
(Date:8/11/2017)... , Aug. 11, 2017  Market ... New York Times article regarding the telemedicine ... according to Kalorama Information.  The article, ... for That"  used information from Kalorama ... Monitoring & Telemedicine Market  (Sleep, Diabetes, ...
(Date:8/10/2017)... ... August 09, 2017 , ... ... week-- as students. From August 14th through the 16th, the University City Science ... in the summer of 2016, provides Philadelphia-based middle school educators an opportunity for ...
(Date:8/10/2017)... ... August 10, 2017 , ... DrugDev and the ... webinar to demonstrate how Good Clinical Practice (GCP) can be used throughout the ... the webinar will discuss the importance of GCP compliance, how sites are affected by ...
Breaking Biology Technology:
(Date:3/30/2017)... YORK , March 30, 2017 Trends, ... type (physiological and behavioral), by technology (fingerprint, AFIS, iris ... voice recognition, and others), by end use industry (government ... and immigration, financial and banking, and others), and by ... Europe , Asia Pacific , ...
(Date:3/24/2017)... , March 24, 2017 The Controller General ... Controller Mr. Abdulla Algeen have received the prestigious international IAIR ... Continue Reading ... ... picture) and Deputy Controller Abdulla Algeen (small picture on the right) have ...
(Date:3/22/2017)... 21, 2017   Neurotechnology , a provider ... today announced the release of the SentiVeillance ... improved facial recognition using up to 10 surveillance, ... computer. The new version uses deep neural-network-based facial ... it utilizes a Graphing Processing Unit (GPU) for ...
Breaking Biology News(10 mins):